Current Trends In TTR Cardiac Amyloidosis Diagnosis And Public Interest

Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, infiltrative disease. The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular related hospitalizations. In 2019 tafamidis became the first FDA-approved treatment for ATTR-CM. In this study we examine the trends in public interest and in ATTR-CM diagnostic testing and stage pre and post approval of tafamidis. Methods GOOGLE© Trends was utilized to capture public interest in cardiac amyloidosis in the pre- and post-tafamidis eras (Era 1: 2010-2018; Era 2: 2019-2020). We conducted a single center retrospective analysis of patients diagnosed with ATTR-CM at a large urban academic center from 2010-2020 and evaluated the usage of Tc PYP testing and demographic and clinical characteristics at time of diagnosis. Results Public interest started to increase in late Era 1 and achieved peak interest in Era 2 (Figure 1). More ATTR patients were diagnosed in Era 2 (n=54 vs n=47), and Tc PYP became the predominant diagnostic method (41% vs 13%, p= <0.00001). No significant differences in Gilmore stage, gender, or TTR type were observed at time of diagnosis (Table 1). Conclusions Public interest in ATTR-ACM increased over time and reached peak interest after FDA approval of tafamidis. In a single center analysis, non-invasive methods have become the leading diagnostic method. The stage at time of diagnosis has remained the same in the pre- and post-tafamidis era. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, infiltrative disease. The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular related hospitalizations. In 2019 tafamidis became the first FDA-approved treatment for ATTR-CM. In this study we examine the trends in public interest and in ATTR-CM diagnostic testing and stage pre and post approval of tafamidis. GOOGLE© Trends was utilized to capture public interest in cardiac amyloidosis in the pre- and post-tafamidis eras (Era 1: 2010-2018; Era 2: 2019-2020). We conducted a single center retrospective analysis of patients diagnosed with ATTR-CM at a large urban academic center from 2010-2020 and evaluated the usage of Tc PYP testing and demographic and clinical characteristics at time of diagnosis. Public interest started to increase in late Era 1 and achieved peak interest in Era 2 (Figure 1). More ATTR patients were diagnosed in Era 2 (n=54 vs n=47), and Tc PYP became the predominant diagnostic method (41% vs 13%, p= <0.00001). No significant differences in Gilmore stage, gender, or TTR type were observed at time of diagnosis (Table 1). Public interest in ATTR-ACM increased over time and reached peak interest after FDA approval of tafamidis. In a single center analysis, non-invasive methods have become the leading diagnostic method. The stage at time of diagnosis has remained the same in the pre- and post-tafamidis era.